FDA emphasizing speed over safety?

On the one hand, everyone would like to see potentially beneficial drugs approved as soon as possible. On the other, no one wants to see the FDA speed heedlessly through the approval process either. As scandals blow up on Capitol Hill over Avandia and other drugs, critics are beginning to question whether the FDA is striking the right balance between speed and safety. Evidence increasingly suggests that the FDA has a habit of silencing internal and external critics--and that safety may be too low on its list of concerns, according to a New York Times analysis. With researchers pointing to dangers from antidepressant use in children, Ketek, Vioxx and now Avandia and Actos prior to the FDA's taking any action, some Congressional players are wondering whether they should crack down on the agency.

To learn more about the ongoing debate:
- read this piece in The New York Times

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.